Helix Biopharma Corp. and Helix Immuno-Oncology to Present at the AACR Annual Meeting 2018 in Chicago
RICHMOND HILL, ONTARIO–(Marketwired – Feb. 6, 2018) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with its wholly-owned subsidiary Helix Immuno-Oncology, it will present a poster entitled: Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast Cancer Models at the American Association for Cancer Research (“AACR”) Annual Meeting 2018 which is taking place on April 14 – 18, 2018 at McCormick Place in Chicago, Illinois.
The presentation will describe preclinical development of V-DOS47 for the potential treatment of certain forms of breast cancer. V-DOS47 is a second therapeutic candidate derived from the DOS47 platform. The DOS47 platform’s first candidate, LDOS47, is currently in multi-centered clinical testing for advanced non-small cell lung cancer.
Presentation details are as follows:
|Session Category: Experimental and Molecular Therapeutics|
|Session Title: Receptor Targeting and the Tumor Microenvironment|
|Session Date and Time: Tuesday April 17, 2018 8:00 AM – 12:00 PM|
|Location: McCormick Place South, Exhibit Hall A, Poster Section 38|
|Poster Board Number: 19|
A copy of the poster will be made available on the Company’s website.
About Helix BioPharma Corp.
Helix BioPharma Corp. is an immune-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug candidate and Chimeric Antigen Receptor (“CAR”) based cell therapies. Helix is currently listed on the TSX and FRANKFURT under the symbol “HBP”.
This news release may contain forward-looking statements and information (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws including, without limitation, those relating to Helix’s operations and strategy and its research and development activities. These statements generally can be identified by forward looking words such as “ongoing”, “excited”, “efforts”, “will” or “modify”, and other similar expressions, are intended to provide information about management’s current plans and expectations.
Forward-looking statements include, without limitation, statements concerning (i) the Company’s ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company’s priority continuing to be L-DOS47; (iii) the Company’s development programs for DOS47, L-DOS47 and V-DOS47; (iv) future expenditures, the insufficiency of the Company’s current cash resources and the need for financing; and (v) future financing requirements and the seeking of additional funding. Forward-looking statements can further be identified by the use of forward-looking terminology such as “ongoing”, “estimates”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.
Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, risks inherent in Helix’s research and development activities and those risks and uncertainties affecting the Company, as more fully described in Helix’s most recent Annual Information Form, including under the headings “Forward-Looking Statements” and “Risk Factors”, filed under Helix’s profile on SEDAR at www.sedar.com (together, the “Helix Risk Factors”). Certain material factors, estimates or assumptions have been applied in making forward-looking statements including, without limitation, the safety and efficacy of the Company’s drug product candidates; that sufficient financing will be obtained in a timely manner to allow the Company to continue operations and implement its clinical trials in the manner and on the timelines anticipated; the timely provision of services and supplies or other performance of contracts by third parties; future costs; the absence of any material changes in business strategy or plans; the timely receipt of required regulatory approvals and strategic partner support and that the factors described in the Helix Risk Factors will not cause the Company’s actual results or events to differ materially from the forward-looking statements. These cautionary statements qualify all such forward-looking statements.
Forward-looking statements and information are based on the beliefs, assumptions, opinions, plans and expectations of Helix’s management on the date of this news release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions, plans or expectations, or other circumstances change, except as required by law.
Helix BioPharma Corp.
9120 Leslie Street, Suite 205
Richmond Hill, Ontario, L4B 3J9